Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,797
Companies 1,769
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Recently updated

FDA-approved

Showing page 98 of 200 · By data quality, then INN

  1. quinethazone

    HYDROMOX

    ORAL FDA: approved

  2. quinidine polygalacturonate

    CARDIOQUIN

    ORAL FDA: approved

  3. quinupristin

    SYNERCID

    INJECTION FDA: approved

  4. quizartinib dihydrochloride

    VANFLYTA

    ORAL FDA: approved

  5. radium ra-223 dichloride

    XOFIGO

    INTRAVENOUS FDA: approved

  6. raltegravir potassium

    RALTEGRAVIR VIATRIS

    ORAL FDA: approved · EMA: application withdrawn · PMDA: approved

    J05AJ01

  7. ramucirumab

    CYRAMZA

    INJECTION FDA: approved · EMA: approved · PMDA: approved

    L01FX06

  8. ranibizumab

    LUCENTIS Novartis Pharmaceuticals

    INJECTION FDA: approved · EMA: approved · TGA: approved · NMPA: clinical trials

    S01LA04

  9. ranibizumab-eqrn

    CIMERLI

    INJECTION FDA: approved

  10. ranibizumab-nuna

    BYOOVIZ

    INJECTION FDA: approved

  11. ranitidine

    APO-RANITIDINE Lacuna Pharma Pty Ltd

    ORAL FDA: approved · TGA: approved

  12. ranitidine bismuth citrate

    TRITEC

    ORAL FDA: approved

  13. rapacuronium bromide

    RAPLON

    INJECTION FDA: approved

  14. rasburicase

    FASTURTEC

    INTRAVENOUS FDA: approved · EMA: approved · PMDA: approved

    V03AF07

  15. ravulizumab-cwvz

    ULTOMIRIS

    INJECTION FDA: approved

  16. raxibacumab

    RAXIBACUMAB

    IV (INFUSION) FDA: approved

  17. regadenoson

    RAPISCAN

    INTRAVENOUS FDA: approved · EMA: approved

    C01EB21

  18. regorafenib

    STIVARGA

    ORAL FDA: approved · EMA: approved · NMPA: clinical trials

    L01EX05

  19. relugolix

    ORGOVYX

    ORAL FDA: approved · EMA: approved · PMDA: approved · NMPA: clinical trials

    H01CC54

  20. remdesivir

    VEKLURY

    INTRAVENOUS FDA: approved · EMA: approved · PMDA: approved

    J05AB16

  21. remibrutinib

    RHAPSIDO

    ORAL FDA: approved · EMA: approved

    L04AA60

  22. remifentanil hydrochloride

    REMIFENTANIL HYDROCHLORIDE

    INJECTION FDA: approved

  23. remimazolam besylate

    BYFAVO

    INTRAVENOUS FDA: approved

  24. repository corticotropin

    H.P. ACTHAR GEL

    INJECTION FDA: approved

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles — INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page — it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.